MX388787B - El uso de amisulpride como un anti-emético. - Google Patents

El uso de amisulpride como un anti-emético.

Info

Publication number
MX388787B
MX388787B MX2019015396A MX2019015396A MX388787B MX 388787 B MX388787 B MX 388787B MX 2019015396 A MX2019015396 A MX 2019015396A MX 2019015396 A MX2019015396 A MX 2019015396A MX 388787 B MX388787 B MX 388787B
Authority
MX
Mexico
Prior art keywords
amisulpride
emetic
nausea
vomiting
therapy
Prior art date
Application number
MX2019015396A
Other languages
English (en)
Other versions
MX2019015396A (es
Inventor
Gabriel Fox
Julian Clive Gilbert
Nicola Cooper
Robert William Gristwood
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42136792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX388787(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Publication of MX2019015396A publication Critical patent/MX2019015396A/es
Publication of MX388787B publication Critical patent/MX388787B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

El amisulpride se usa en la terapia de náusea, vómito o bascas. La terapia puede utilizar una formulación inyectable novedosa, en forma de dosificación unitaria, que comprende menor que 50 mg de amisulpride.
MX2019015396A 2010-03-11 2011-03-10 El uso de amisulpride como un anti-emético. MX388787B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1004020.2A GB201004020D0 (en) 2010-03-11 2010-03-11 New therapeutic use
PCT/GB2011/050472 WO2011110854A2 (en) 2010-03-11 2011-03-10 The use of amisulpride as an anti-emetic

Publications (2)

Publication Number Publication Date
MX2019015396A MX2019015396A (es) 2020-02-07
MX388787B true MX388787B (es) 2025-03-20

Family

ID=42136792

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2012010411A MX2012010411A (es) 2010-03-11 2011-03-10 El uso amisulpride como un anti-emetico.
MX2019015396A MX388787B (es) 2010-03-11 2011-03-10 El uso de amisulpride como un anti-emético.
MX2015003664A MX370629B (es) 2010-03-11 2011-03-10 El uso de amisulpride como un anti-emetico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012010411A MX2012010411A (es) 2010-03-11 2011-03-10 El uso amisulpride como un anti-emetico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015003664A MX370629B (es) 2010-03-11 2011-03-10 El uso de amisulpride como un anti-emetico.

Country Status (26)

Country Link
US (12) US9084765B2 (es)
EP (3) EP2796171B1 (es)
JP (2) JP5886213B2 (es)
KR (1) KR101738201B1 (es)
CN (1) CN102892407B (es)
AU (1) AU2011225898B2 (es)
BR (1) BR112012022746B1 (es)
CA (1) CA2792392C (es)
CY (3) CY1115485T1 (es)
DK (3) DK2544657T3 (es)
EA (1) EA030335B1 (es)
ES (3) ES2496092T3 (es)
GB (1) GB201004020D0 (es)
HR (3) HRP20140744T1 (es)
HU (1) HUE037088T2 (es)
IL (1) IL221746A (es)
LT (1) LT2796171T (es)
MX (3) MX2012010411A (es)
NO (1) NO2796171T3 (es)
NZ (1) NZ602279A (es)
PL (3) PL2567690T3 (es)
PT (3) PT2796171T (es)
RS (3) RS53467B (es)
SI (3) SI2544657T1 (es)
SM (3) SMT201800188T1 (es)
WO (1) WO2011110854A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
CN104435861A (zh) * 2014-12-22 2015-03-25 济南伟传信息技术有限公司 一种治疗妊娠剧吐的茶
GB201506116D0 (en) * 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
EP3344962A4 (en) 2015-09-02 2019-03-13 California Institute of Technology METHOD AND DEVICE FOR THE SPECTROSCOPIC DETECTION OF LOW CONCENTRATIONS OF SULFUR HYDROGEN GAS
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) * 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN118593482A (zh) 2017-12-05 2024-09-06 赛诺维信制药公司 非外消旋混合物及其用途
US10377708B2 (en) 2017-12-05 2019-08-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
JP2022535893A (ja) 2019-06-04 2022-08-10 サノビオン ファーマシューティカルズ インク 放出調節製剤およびその使用
US20220323409A1 (en) * 2019-06-04 2022-10-13 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
CN115867271A (zh) * 2020-07-06 2023-03-28 阿卡西亚制药有限公司 术后恶心和呕吐的疗法
US20250206757A1 (en) 2022-03-21 2025-06-26 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
JP2025513071A (ja) 2022-04-14 2025-04-22 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
CN121002014A (zh) 2022-12-15 2025-11-21 加舒布鲁姆生物公司 具有glp-1激动剂活性的化合物的盐和固体形式
CN120693338A (zh) 2022-12-22 2025-09-23 加舒布鲁姆生物公司 杂环的glp-1激动剂
WO2024131869A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
AU2024222719A1 (en) 2023-02-16 2025-08-21 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
TW202506102A (zh) 2023-06-30 2025-02-16 美商迦舒布魯姆生物有限公司 雜環的glp-1促效劑
AR133240A1 (es) 2023-07-13 2025-09-10 Aconcagua Bio Inc Compuestos, composiciones y métodos
TW202519220A (zh) 2023-07-13 2025-05-16 美商雅空嘉閣生物公司 化合物、組合物及方法
WO2025045208A1 (en) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
DE10163421A1 (de) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
DE102005013726A1 (de) * 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
WO2007067714A2 (en) * 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
US20070190145A1 (en) 2006-01-27 2007-08-16 Eurand, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
WO2007096489A1 (fr) * 2006-02-17 2007-08-30 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US7825156B2 (en) * 2007-02-02 2010-11-02 Copharms Method of treating bipolar depression with a benzamide derivative
CA2905541C (en) * 2008-01-09 2020-02-11 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
WO2009126931A2 (en) * 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use

Also Published As

Publication number Publication date
CA2792392C (en) 2018-06-19
EP2544657B1 (en) 2014-07-16
HRP20140745T1 (hr) 2014-09-26
RS57032B1 (sr) 2018-05-31
NO2796171T3 (es) 2018-06-30
KR101738201B1 (ko) 2017-05-19
US9084765B2 (en) 2015-07-21
US9889118B2 (en) 2018-02-13
RS53467B (sr) 2014-12-31
CN102892407B (zh) 2016-03-23
EA201290833A1 (ru) 2013-09-30
US20210228543A1 (en) 2021-07-29
JP6279526B2 (ja) 2018-02-14
HUE037088T2 (hu) 2018-08-28
KR20130045241A (ko) 2013-05-03
PL2544657T3 (pl) 2014-10-31
HRP20180436T1 (hr) 2018-05-04
HRP20140744T1 (hr) 2014-09-26
BR112012022746A2 (pt) 2016-07-05
WO2011110854A2 (en) 2011-09-15
SMT201800188T1 (it) 2018-07-17
CN102892407A (zh) 2013-01-23
PT2544657E (pt) 2014-09-03
EP2567690B1 (en) 2014-07-16
US20130022689A1 (en) 2013-01-24
AU2011225898A1 (en) 2012-10-04
CY1115487T1 (el) 2017-01-04
JP5886213B2 (ja) 2016-03-16
CA2792392A1 (en) 2011-09-15
EP2796171B1 (en) 2018-01-31
US8686019B2 (en) 2014-04-01
MX2019015396A (es) 2020-02-07
SI2567690T1 (sl) 2014-12-31
US10525033B2 (en) 2020-01-07
PT2567690E (pt) 2014-09-03
US20150335616A1 (en) 2015-11-26
ES2665418T3 (es) 2018-04-25
SMT201400126B (it) 2015-05-05
EP2567690A1 (en) 2013-03-13
EA030335B1 (ru) 2018-07-31
PT2796171T (pt) 2018-04-24
US20140147517A1 (en) 2014-05-29
DK2567690T3 (da) 2014-08-11
US20170087128A1 (en) 2017-03-30
ES2496092T3 (es) 2014-09-18
MX370629B (es) 2019-12-18
US20250186394A1 (en) 2025-06-12
US20200093792A1 (en) 2020-03-26
NZ602279A (en) 2014-08-29
CY1115485T1 (el) 2017-01-04
DK2796171T3 (en) 2018-05-07
US20180042896A1 (en) 2018-02-15
US20180353473A1 (en) 2018-12-13
US10085970B2 (en) 2018-10-02
US20130022688A1 (en) 2013-01-24
US20220296570A1 (en) 2022-09-22
SMT201400127B (it) 2015-05-05
US9119836B2 (en) 2015-09-01
AU2011225898B2 (en) 2014-07-03
DK2544657T3 (da) 2014-08-11
MX2012010411A (es) 2012-11-30
PL2796171T3 (pl) 2018-07-31
WO2011110854A3 (en) 2011-11-10
JP2013522181A (ja) 2013-06-13
US12194022B2 (en) 2025-01-14
CY1120170T1 (el) 2018-12-12
US20230144973A1 (en) 2023-05-11
JP2016028090A (ja) 2016-02-25
GB201004020D0 (en) 2010-04-21
LT2796171T (lt) 2018-05-10
SI2544657T1 (sl) 2014-12-31
EP2544657A2 (en) 2013-01-16
PL2567690T3 (pl) 2014-11-28
SI2796171T1 (en) 2018-05-31
HK1179152A1 (zh) 2013-09-27
EP2796171A1 (en) 2014-10-29
ES2496099T3 (es) 2014-09-18
US9545426B2 (en) 2017-01-17
IL221746A (en) 2017-03-30
RS53466B (sr) 2014-12-31
BR112012022746B1 (pt) 2021-09-28

Similar Documents

Publication Publication Date Title
MX388787B (es) El uso de amisulpride como un anti-emético.
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
CL2012000248A1 (es) Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina.
CL2008000418A1 (es) Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica.
PE20141406A1 (es) 4-(8-metoxi-1-((1-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1h-imidazo[4,5-c]quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor bromodominio
SV2011003853A (es) Compuestos organicos
CL2012000469A1 (es) Composición farmacéutica que comprende un compuesto conjugado de insulina de absorcion lenta; un envase; una suspensión que comprende la composición y su método de preparación; su uso para el tratamiento o prevención de una patología asociado a deficiencia de insulina, como diabetes; un kit.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
PE20211094A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
ECSP10010112A (es) Compuestos de tienopirimidina y pirazolopirimidina y su uso como inhibidores de mtor cinasa y pi3 cinasa
CL2013002171A1 (es) Composicion fungicida y bactericida que comprende compuestos organicos volatiles de origen natural; uso de la composición.
CL2012002173A1 (es) Combinacion de al menos un estimulador o activador de la sgc con un inhibidor de la pde5; formulacion farmaceutica; y uso para el tratamiento de la fibrosis quistica.
EA201200143A1 (ru) Антибактериальная композиция для ротовой полости
CL2012001950A1 (es) Uso de una cepa bacteriana probiotico en la fabricacion de un medicamento o composicion nutricional en humanos o animales para alterar los patrones del sueño
CL2011001811A1 (es) Un metodo para tratar un paciente que ha sufrido un infarto agudo al miocardio que comprende el uso de un agente antifibrotico.
GT201400111A (es) Triazolopiridinas sustituidas
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
CL2011001712A1 (es) Combinacion de 0,1 a 1 mg de al menos un estimulador de sgc seleccionado de un grupo definido con 2,5 a 20 mg de un inhibidor de pde5 seleccionado de otro grupo; formulacion farmaceutica que la comprende y uso en el tratamiento de la disfuncion sexual masculina.
NI201100149A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia.
CO6351779A2 (es) Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
CL2009001089A1 (es) Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
ECSP10010464A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares
CL2012000478A1 (es) Formas cristalinas de 4,5,6,7-tetrahidro-11-metoxi-2-[(4-metil-1-piperazinil)metil]-1h-ciclopenta[alfa]pirrolo[3,4-c]carbazol-1,3(2h)-diona; composicion farmaceutica; y uso en el tratamiento de cancer.
DOP2010000361A (es) Dronedarona para la prevencion de la cardioversion